Literature DB >> 33718461

Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective.

Jing Cui1,2, Yanfei Liu3, Yiwen Li1,2,4, Fengqin Xu2,4, Yue Liu1,2,4.   

Abstract

Type 2 diabetes mellitus (T2DM) and its complications are seriously affecting public health worldwide. Myocardial infarction (MI) is the primary cause of death in patients with T2DM. T2DM patients without a history of coronary artery disease (CAD) have the same risk of major coronary events as those with CAD; T2DM patients with a history of MI have >40% risk of recurrence of MI. Thus, CAD in patients with T2DM needs to be treated actively to reduce the risk of MI. The cardiology community focused on the role of T2DM in the development of CAD and on the related issues of T2DM and MI with respect to comorbidities, prognosis, drug therapy, and heredity. In this mini review, the latest progress of clinical evidence-based research between T2DM and MI in recent years was reviewed, and the possible research directions in this field were considered and prospected.
Copyright © 2021 Cui, Liu, Li, Xu and Liu.

Entities:  

Keywords:  drug; evidence-based medicine; myocardial infarction; sodium-glucose cotransporter-2 inhibitor; type 2 diabetes

Year:  2021        PMID： 33718461      PMCID： PMC7943438          DOI： 10.3389/fcvm.2021.644189

Source DB:  PubMed          Journal:  Front Cardiovasc Med        ISSN： 2297-055X


  53 in total

1.  Newly Discovered Abnormal Glucose Tolerance in Patients With Acute Myocardial Infarction and Cardiovascular Outcomes: A Meta-analysis.

Authors:  Nitchakarn Laichuthai; Muhammad Abdul-Ghani; Mikhail Kosiborod; Wasita Warachit Parksook; Stephen J Kerr; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2020-08       Impact factor: 19.112

Review 2.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

Authors:  Francesco Cosentino; Peter J Grant; Victor Aboyans; Clifford J Bailey; Antonio Ceriello; Victoria Delgado; Massimo Federici; Gerasimos Filippatos; Diederick E Grobbee; Tina Birgitte Hansen; Heikki V Huikuri; Isabelle Johansson; Peter Jüni; Maddalena Lettino; Nikolaus Marx; Linda G Mellbin; Carl J Östgren; Bianca Rocca; Marco Roffi; Naveed Sattar; Petar M Seferović; Miguel Sousa-Uva; Paul Valensi; David C Wheeler
Journal:  Eur Heart J       Date:  2020-01-07       Impact factor: 29.983

3.  IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.

Authors:  N H Cho; J E Shaw; S Karuranga; Y Huang; J D da Rocha Fernandes; A W Ohlrogge; B Malanda
Journal:  Diabetes Res Clin Pract       Date:  2018-02-26       Impact factor: 5.602

Review 4.  Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes.

Authors:  Manasi S Shah; Michael Brownlee
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

5.  Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.

Authors:  Huang-Tz Ou; Kai-Cheng Chang; Chung-Yi Li; Jin-Shang Wu
Journal:  Br J Clin Pharmacol       Date:  2017-02-27       Impact factor: 4.335

Review 6.  EMPA-REG OUTCOME: The Endocrinologist's Point of View.

Authors:  Leigh Perreault
Journal:  Am J Cardiol       Date:  2017-05-17       Impact factor: 2.778

Review 7.  Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2020-08       Impact factor: 6.447

8.  A potent risk model for predicting new-onset acute coronary syndrome in patients with type 2 diabetes mellitus in Northwest China.

Authors:  Jun Lyu; Zhiying Li; Huiyi Wei; Dandan Liu; Xiaoxian Chi; Da-Wei Gong; Qingbin Zhao
Journal:  Acta Diabetol       Date:  2020-02-01       Impact factor: 4.280

9.  Increased Risk of Myocardial Infarction Among Patients With Type 2 Diabetes Who Carry the Common rs10830963 Variant in the MTNR1B Gene.

Authors:  Xiao Tan; Christian Benedict
Journal:  Diabetes Care       Date:  2020-07-02       Impact factor: 19.112

10.  Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.

Authors:  Chun-Ting Yang; Chen-Yi Yang; Huang-Tz Ou; Shihchen Kuo
Journal:  Cardiovasc Diabetol       Date:  2020-06-13       Impact factor: 9.951
View more
  10 in total

1.  Significance of Lipid Profile Parameters in Predicting Pre-Diabetes.

Authors:  O H Jasim; M M Mahmood; A H Ad'hiah
Journal:  Arch Razi Inst       Date:  2022-02-28

2.  In-hospital risk stratification algorithm of Asian elderly patients.

Authors:  Sazzli Kasim; Sorayya Malek; Song Cheen; Muhammad Shahreeza Safiruz; Wan Azman Wan Ahmad; Khairul Shafiq Ibrahim; Firdaus Aziz; Kazuaki Negishi; Nurulain Ibrahim
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

Review 3.  Impact of diabetes on outcomes of cardiogenic shock: A systematic review and meta-analysis.

Authors:  Chao Luo; Feng Chen; Lingpei Liu; Zuanmin Ge; Chengzhen Feng; Yuehua Chen
Journal:  Diab Vasc Dis Res       Date:  2022 Sep-Oct       Impact factor: 3.541

4.  Bioinformatic Analysis for Potential Biomarkers and Therapeutic Targets of T2DM-related MI.

Authors:  Chan Li; Zhaoya Liu
Journal:  Int J Gen Med       Date:  2021-08-10

5.  Undiagnosed Impaired Glucose Tolerance and Type-2 Diabetes in Acute Myocardial Infarction Patients: Fequency, Characteristics and Long-Term Mortality.

Authors:  Timo Schmitz; Eva Harmel; Margit Heier; Annette Peters; Jakob Linseisen; Christa Meisinger
Journal:  Front Cardiovasc Med       Date:  2022-04-25

6.  Exacerbated post-infarct pathological myocardial remodelling in diabetes is associated with impaired autophagy and aggravated NLRP3 inflammasome activation.

Authors:  Shuai Mao; Peipei Chen; Wenjun Pan; Lei Gao; Minzhou Zhang
Journal:  ESC Heart Fail       Date:  2021-12-28

Review 7.  Comorbidity of Type 2 Diabetes Mellitus and Depression: Clinical Evidence and Rationale for the Exacerbation of Cardiovascular Disease.

Authors:  Mengmeng Zhu; Yiwen Li; Binyu Luo; Jing Cui; Yanfei Liu; Yue Liu
Journal:  Front Cardiovasc Med       Date:  2022-03-10

8.  Influence of the Triglyceride-Glucose Index on Adverse Cardiovascular and Cerebrovascular Events in Prediabetic Patients With Acute Coronary Syndrome.

Authors:  Qianyun Guo; Xunxun Feng; Bin Zhang; Guangyao Zhai; Jiaqi Yang; Yang Liu; Yuyang Liu; Dongmei Shi; Yujie Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-22       Impact factor: 5.555

Review 9.  The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus.

Authors:  Bertram Pitt; Gabriel Steg; Lawrence A Leiter; Deepak L Bhatt
Journal:  Cardiovasc Drugs Ther       Date:  2021-11-09       Impact factor: 3.947

Review 10.  Effect of Glucose Levels on Cardiovascular Risk.

Authors:  Anastasia V Poznyak; Larisa Litvinova; Paolo Poggio; Vasily N Sukhorukov; Alexander N Orekhov
Journal:  Cells       Date:  2022-09-28       Impact factor: 7.666
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.